MedTrace Logo

Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole

NCT01094275 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2018-01-31

No results posted yet for this study

Summary

Clopidogrel, an inhibitor of ADP induced platelet aggregation and activation, is one of the most commonly used drugs in patients with cardiovascular disease. The specific aim of the proposed study is to determine whether the interaction between proton-pump inhibitors (PPIs) and clopidogrel is dependent on CYP2C19 haplotype.

Conditions

Interventions

DRUG

Clopidogrel 75mg, Omeprazole 20mg

Clopidogrel and or Omeprazole as applicable

Sponsors & Collaborators

  • Neil Kleiman, MD

    lead OTHER

Principal Investigators

  • Neal S Kleiman, MD · Methodist DeBakey Heart Center.

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01094275 on ClinicalTrials.gov